0001185185-26-001339
SEC filingRevenue and gross profit rose significantly in FY2025, driven by new product launches and a one-time reduction in cost of goods sold, yet the company remains deeply unprofitable with operating and net losses narrowing only in magnitude — reflecting persistent structural cost pressures and ongoing reliance on external funding.
Gross profit more than doubled to $339.1K in FY2025, rising 99.8% year-over-year. This improvement was enabled by a material decline in cost of goods sold — a dynamic management explicitly ties to a one-time process related to expired products in FY2024. While the authoritative financial packet does not quantify the FY2024 write-off amount, management’s commentary confirms its occurrence and timing, establishing it as a non-recurring factor. As a result, gross margin expanded to 86.6%, but this reflects an exceptional cost reduction rather than sustainable operational leverage.
Revenue grew 32.9% to $391.7K, with management attributing the increase directly to the launch of new products. This growth occurred without evidence of broad-based market penetration or scaling of existing offerings. The absence of segment-level disclosures or customer concentration data limits visibility into diversification or durability of this revenue stream. Critically, revenue remains materially below total operating expenses, reinforcing that top-line expansion has not yet altered the fundamental cost-revenue imbalance.
Operating income improved to -$382.9K, representing a 51.1% reduction in loss magnitude versus FY2024. However, operating margin stood at -97.8%, confirming that nearly all revenue is consumed before covering operating costs. Management notes decreases in selling, office, professional, reserve, and stock compensation expenses — yet the absolute level of SG&A remains structurally disproportionate to revenue. Without consolidated commercial operations across its health-tech ventures (Purecell, Sijinsai JV, GOF Biotechnologies), SG&A functions as corporate overhead rather than growth-enabling investment.
Net cash used in operating activities improved to -$332.9K from -$615.6K, signaling modest progress in cash flow efficiency. Still, the company generated negative operating cash flow for the second consecutive year. Management identifies liquidity as dependent on funds from operations, accounts receivable and payable management, and capital expenditures — yet acknowledges that future majority shareholders must provide all working capital. This statement, drawn directly from Item 7, frames liquidity not as a transient challenge but as a defining feature of the company’s current capital structure and operational model.